MYOS

MISSISSAUGA, Ontario & CEDAR KNOLLS, N.J.--(BUSINESS WIRE)--MedAvail, Inc. (“MedAvail”), a leading technology-enabled pharmacy organization that embeds pharmacy services directly into clinics and other points of care through its proprietary technology, announced the completion of its previously announced business combination with MYOS RENS Technology, Inc. (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition that helps build lean muscle. The combined company will focus on the MedAvail business and its shares will trade on the Nasdaq Capital Market under the new trading symbol "MDVL." The current MYOS RENS muscle health busi

CEDAR KNOLLS, N.J., Nov. 17, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or the "Company") (NASDAQ: MYOS) As previously announced, on June 30, 2020, MYOS RENS Technology, Inc., a Nevada corporation ("MYOS"), and MedAvail, Inc., a privately-held Delaware corporation ("MedAvail"), entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), by and among MYOS, MedAvail, and Matrix Merger Sub, Inc., a newly-created wholly-owned subsidiary of MYOS ("Merger Sub"), pursuant to which, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into MedAvail, with MedAvail being the surviving corp

CEDAR KNOLLS, N.J., Nov. 12, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or the "Company") (NASDAQ: MYOS) As previously announced, on June 30, 2020, MYOS RENS Technology, Inc., a Nevada corporation ("MYOS"), and MedAvail, Inc., a privately-held Delaware corporation ("MedAvail"), entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), by and among MYOS, MedAvail, and Matrix Merger Sub, Inc., a newly-created wholly-owned subsidiary of MYOS ("Merger Sub"), pursuant to which, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into MedAvail, with MedAvail being the surviving corp

CEDAR KNOLLS, N.J., Nov. 6, 2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or the "Company") (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition that helps build lean muscle, announced today its results for the three and nine months ended September 30, 2020.  "Q3 results have shown that Myos met the challenges of the new and uncertain "normal" with sensitivity, creativity and smarter, more aggressive marketing which helped us build deeper business relationships with our customers. This resulted in a significant increase in revenues while decreasing expenses during the quarter," said Joseph Mannello, CEO of MYOS.  "These

NEW YORK, Oct. 17, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: MVC Capital, Inc. (NYSE: MVC) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Barings BDC, Inc. Under the terms of the merger agreement, MVC Capital shareholders will receive 0.94024 shares of Barings BDC and $0.39492 in cash for each share of MVC Capital stock. Visit our website to learn more about your legal rights and options: https://halpersadeh.com/actions/mvc-capital-inc-mvc-stock-merger-barings-bdc. American Renal Associates Holdings, Inc. (NYSE: ARA) concerning potential violations of